| Entry |
|
|---|
| Name |
Triazolam (JP18/USP/INN);
Halcion (TN) |
|---|
| Product |
|
|---|
| Generic |
TRIAZOLAM (A-S Medication Solutions), TRIAZOLAM (A-S Medication Solutions), TRIAZOLAM (Aphena Pharma Solutions - Tennessee), TRIAZOLAM (Bryant Ranch Prepack), TRIAZOLAM (Greenstone LLC), TRIAZOLAM (Hikma Pharmaceuticals USA), TRIAZOLAM (Ingenus Pharmaceuticals), TRIAZOLAM (PD-Rx Pharmaceuticals), TRIAZOLAM (PD-Rx Pharmaceuticals), TRIAZOLAM (Zydus Lifesciences Limited), TRIAZOLAM (Zydus Pharmaceuticals USA) |
|---|
| Formula |
C17H12Cl2N4
|
|---|
| Exact mass |
342.0439
|
|---|
| Mol weight |
343.21
|
|---|
| Structure |
|
|---|
| Simcomp |
|
|---|
| Class |
Neuropsychiatric agent
DG01835 Benzodiazepine sedative-hypnotics
DG03202 Hypnotic
DG01567 GABA-A receptor agonist
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
|
|---|
| Remark |
| Therapeutic category: | 1124 |
|
|---|
| Efficacy |
Sedative-hypnotic |
|---|
| Disease |
|
|---|
| Comment |
Benzodiazepine derivative
|
|---|
| Target |
|
|---|
| Pathway |
| hsa04080 | Neuroactive ligand-receptor interaction |
|
|---|
| Metabolism |
Enzyme: CYP3A4 [HSA: 1576]
|
|---|
| Interaction |
|
|---|
| Structure map |
| map07230 | GABA-A receptor agonists/antagonists |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
N NERVOUS SYSTEM
N05 PSYCHOLEPTICS
N05C HYPNOTICS AND SEDATIVES
N05CD Benzodiazepine derivatives
N05CD05 Triazolam
D00387 Triazolam (JP18/USP/INN) <JP/US>
USP drug classification [BR:br08302]
Sleep Disorder Agents
Sleep Promoting Agents
Triazolam
D00387 Triazolam (JP18/USP/INN)
Therapeutic category of drugs in Japan [BR:br08301]
1 Agents affecting nervous system and sensory organs
11 Agents affecting central nervous system
112 Hypnotics and sedatives, anxiolytics
1124 Benzodiazepins
D00387 Triazolam (JP18/USP/INN)
Drug groups [BR:br08330]
Neuropsychiatric agent
DG01835 Benzodiazepine sedative-hypnotics
D00387 Triazolam
DG03202 Hypnotic
D00387 Triazolam
DG01567 GABA-A receptor agonist
D00387 Triazolam
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
D00387 Triazolam
Drug classes [BR:br08332]
Neuropsychiatric agent
DG03202 Hypnotic
D00387 Triazolam
Target-based classification of drugs [BR:br08310]
Ion channels
Ligand-gated ion channels
GABA (ionotropic)
GABR
D00387 Triazolam (JP18/USP/INN) <JP/US>
Drugs listed in the Japanese Pharmacopoeia [BR:br08311]
Chemicals
D00387 Triazolam
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D00387
Narcotics and psychotropics in Japan [br08308.html]
Psychotropics by Cabinet order Article 3 (78 substances)
D00387
|
|---|
| Other DBs |
|
|---|
| KCF data |
ATOM 23
1 C2y C 22.2631 -15.9778
2 C8y C 21.4204 -14.7974
3 C8y C 21.7559 -13.4397
4 N4y N 23.0177 -12.8611
5 N2x N 23.6699 -15.9330
6 C8y C 24.2722 -13.4839
7 C1x C 24.5589 -14.8536
8 C8x C 20.7480 -12.4706
9 C8x C 19.4051 -12.8589
10 C8y C 19.0697 -14.2167
11 C8x C 20.0775 -15.1855
12 X Cl 17.7039 -14.6114
13 C8y C 21.6282 -17.1584
14 C8x C 20.2256 -17.1584
15 C8x C 19.5251 -18.3717
16 C8x C 20.2256 -19.5850
17 C8x C 21.6282 -19.5850
18 C8y C 22.3287 -18.3717
19 X Cl 23.7406 -18.3718
20 N5x N 25.2522 -12.4832
21 N5x N 24.6033 -11.2420
22 C8y C 23.2224 -11.4756
23 C1a C 22.2334 -10.5070
BOND 26
1 3 4 1
2 1 5 2
3 4 6 1
4 2 3 1
5 5 7 1
6 1 2 1
7 6 7 1
8 3 8 2
9 8 9 1
10 9 10 2
11 10 11 1
12 2 11 2
13 10 12 1
14 1 13 1
15 13 14 1
16 14 15 2
17 15 16 1
18 16 17 2
19 17 18 1
20 13 18 2
21 18 19 1
22 6 20 2
23 20 21 1
24 21 22 2
25 4 22 1
26 22 23 1
|
|---|
